

# **PLEOMORPHIC SARCOMAS**

**ANGELO PAOLO DEI TOS**

**DEPARTMENTS OF PATHOLOGY  
AND ONCOLOGY**  
TREVISO, ITALY

**APDEITOS@ULSS.TV.IT**


**esmo.org**

# DISCLOSURE SLIDE

No conflicts to declare

# WHO Classification of Tumours of Soft Tissue and Bone

Edited by Christopher D.M. Fletcher, Julia A. Bridge, Pancras C.W. Hogendoorn, Fredrik Mertens



## Adipocytic tumours

- Well differentiated / dedifferentiated liposarcoma
- Myxoid / round cell liposarcoma
- Pleomorphic liposarcoma

## Fibroblastic / myofibroblastic tumours

- Fibromatosis (desmoid)
- DFSP
- Solitary fibrous tumour / haemangiopericytoma
- IMT
- Low grade myofibroblastic sarcoma
- Infantile fibrosarcoma
- Adult fibrosarcoma
- Mixofibrosarcoma
- SEF
- LGFMS

## Smooth muscle tumours

- Leiomyosarcoma

## Skeletal muscle tumours

- Embryonal rhabdomyosarcoma
- Alveolar rhabdomyosarcoma
- Pleomorphic rhabdomyosarcoma

## Vascular tumours

- Epithelioid haemangioendothelioma
- Angiosarcoma of soft tissue

## GIST

## Nerve sheath tumors

- MPNST
- Malignant GCT

## Chondro-osseous tumours

- Mesenchymal chondrosarcoma
- Extraskeletal osteosarcoma

## Tumours of uncertain differentiation

- Synovial sarcoma
- Epithelioid sarcoma
- Alveolar soft part sarcoma
- Clear cell sarcoma of soft tissue
- Extraskeletal myxoid chondrosarcoma
- Extraskeletal Ewing sarcoma
- Desmoplastic small round cell tumour
- Extra-renal rhabdoid tumour
- Malignant mesenchymoma
- Malignant PEComa
- Intimal sarcoma

**SARCOMA & GIST CONFERENCE 2016**







# How WHO classification was reshaped

- Pathologists and Cytogeneticists
- Integration of immunophenotype and genetics
- Broad authorships
- Discussion “word by word” of all contributions

# Major changes

- Definition of tumor category (both in bone and soft tissue)
- Genetics now part of tumor entity definition
- MFH and HPC formally abolished
- Undifferentiated sarcoma category
- New entities incorporated
  - ◆ i.e. pseudomyogenic hemangioendothelioma
- Few entities reshaped
  - ◆ GCA now part of SFT spectrum
- GIST, Neural neoplasms, AFX
- Atypical chondrogenic tumors
- Ewing sarcoma better described

# MFH story


- 1963: Ozzello, Stout, Lattes, and Murray
- 1970-1980: Kempson, Enzinger and Weiss
- 1986: Brooks
- 1992: Fletcher
- 2002: WHO








**Dr. Murray**



**Dr. Stout**

# The MFH Legacy

- Pleomorphic and Storiform MFH
- Myxoid MFH
- Giant cell MFH
- Inflammatory MFH
- Angiomatoid MFH



## Pleomorphic Malignant Fibrous Histiocytoma: Fact or Fiction?


A Critical Reappraisal Based on 159 Tumors Diagnosed  
as Pleomorphic Sarcoma

Christopher D.M. Fletcher, M.D., M.R.C.Path.


- Until 1992 MFH = most frequent soft tissue sarcoma
- Morphology + IHC reclassifies most MFH
  - Plep LPS, LMS; RMS, MPNST, DDLPS
- MFH = morphologic pattern
  - NHL
  - Metastatic Melanoma
  - Sarcomatoid Carcinoma




ALCL




ALK1



SarcCA




CK







LMS




RMS



LPS



MPNST









# Pleomorphic liposarcoma

- 5% of all liposarcomas
- M > F, 6th decade
- Lower limbs, upper limbs, retroperitoneum
- Metastatic rate: 30-50%
- 5 yr survival rate = 57%
- Complex Karyotypic aberrations
- TP53 alterations in 50% of cases








# MFH: What's Left?

- Myxoid MFH = myxofibrosarcoma
- Inflammatory MFH = dedifferentiated LPS
- Giant cell MFH = giant cell tumor of soft tissues, extraskeletal OS, other sarcomas (mostly leiomyosarcomas) containing giant cells
- Angiomatoid (m)FH = moved to lesions of uncertain “histogenesis”
- Pleomorphic MFH = Undifferentiated Pleomorphic Sarcoma



A"MFH





## Angiomatoid Fibrous Histiocytoma

(rarely metastasizing lesion)

- t(12;22)(q13;q12)  
*EWSR1-ATF1*  
*(in unusual site)*

**Sommers et al 2005**

- t(2;22)(q33;q12)  
*EWSR1-CREB1*  
*(majority)*

**Rossi et al 2007**

- t(12;16)(q13;p11)  
*FUS-ATF1*

**Waters et al 2000**

## Clear cell sarcoma (malignant lesion )

- t(12;22)(q13;q12)  
*EWSR1-ATF1*  
*(most frequent in soft tissue)*



**Zucman et al 1993**

- t(2;22)(q33;q12)  
*EWSR1-CREB1*  
*(mostly in GI tract)*

*lack melanocytic markers*

**Antonescu et al 2006**

“Inflammatory MFH” = Dedifferentiated LPS



MDM2




# Myxofibrosarcoma





- Angervall, 1977
  - Myxoid MFH of Enzinger
- Spectrum of fibroblastic myxoid lesions
- High grade = myxoid “MFH”
- Histologic grade related to clinical outcome

# Myxofibrosarcoma

- Elderly patients
  - Very rare < 20 years
- Lower limbs > upper limbs > limb girdles
- Most cases in retroperitoneum = dedifferentiated LPS
- 2/3 subcutis, 1/3 deep seated
- IHC: MSA and SMA (focal)










# Myxofibrosarcoma

- Low grade rarely metastasize
- Local recurrence: 50%
  - independent of grade
- Surgical resection is a challenge
  - Main Goal: wide margins
- High grade 30% metastatic rate
  - Lungs > bone > LN
- Overall SR @ 5 years = 60%



# Epithelioid Myxofibrosarcoma

- . Elderly patients
- . Limbs
- . 50% metastatic rate
  - Lungs > bone
- . 73% recurrence rate
- . Overall SR @ 5 years = 37%
- . More aggressive than ordinary myxofibrosarcoma




# Giant Cell MFH


- Histiocytic tumors
- GCT of soft tissues
  - ◆ Indolent clinical behavior
- Extraskeletal Osteosarcoma
  - ◆ Neoplastic osteoid
- Other high grade pleomorphic sarcomas with OC-like giant cells




LMS




E-OS



LMS



SATB2





# Pleomorphic Sarcomas: Is there a need for subtyping?

- Identification of non-mesenchymal neoplasms
- Myogenic differentiation related to worse prognosis
- Myxoid areas related to better prognosis
- Different treatment options for myogenic sarcomas


JCO 2001; 19:3045-3050.

© 2001 American Society for Clinical Oncology

## Clinicopathologic Re-Evaluation of 100 Malignant Fibrous Histiocytomas: Prognostic Relevance of Subclassification

By Christopher D.M. Fletcher, Pelle Gustafson, Anders Rydholm, Helena Willén, Måns Åkerman



Myogenin





# Dedifferentiated liposarcoma

- Evans, 1979
- Retroperitoneum of adults
- De novo (90%)
- Abrupt transition from WD liposarcoma to high grade non lipogenic sarcoma
- Rarely two components co-mingled
- Rarely non lipogenic component is low grade
- Rarely dedifferentiated component lipogenic
- MDM2/CDK4 overexpression/amplification





VOLUME 27 • NUMBER 1 • JANUARY 1 2009

JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT

## Aggressive Surgical Policies in a Retrospectively Reviewed Single-Institution Case Series of Retroperitoneal Soft Tissue Sarcoma Patients

*Alessandro Gronchi, Salvatore Lo Vullo, Marco Fiore, Chiara Mussi, Silvia Stacchiotti, Paola Collini, Laura Lozza, Elisabetta Pennacchioli, Luigi Mariani, and Paolo Giovanni Casali*

VOLUME 27 • NUMBER 1 • JANUARY 1 2009

JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT





## Primary Retroperitoneal Sarcomas: A Multivariate Analysis of Surgical Factors Associated With Local Control

*Sylvie Bonvalot, Michel Rivoire, Marine Castaing, Eberhard Stoeckle, Axel Le Cesne, Jean Yves Blay, and Agnès Laplanche*


# Undifferentiated Pleomorphic Sarcomas

- Pleomorphic
- Epithelioid
- Round cell
  - Ewing like tumors with non canonical morphology as well as non ETS associated fusions (CIC-DUX4 etc.)
- Spindle cell












# Undifferentiated small round sarcomas

## Ewing-sarcoma like

### CIC-DUX4 fusions



Italiano et al 2012

### CIC (19q13.1) variant translocation




$t(X;19)(q13;q13.1)/CIC-FOXOA$

- 63-year-old man  
Sugita et al 2014
- 13 year-old boy  
Solomon et al 2014
- ???

Brohl et al. 2014\*








# Undifferentiated small round sarcomas Ewing-sarcoma like

## *BCOR-CCNB3* fusion



- RNA-Sequencing      Cryptic rearrangement
- Gene expression profile no EWSR1-ETS signature
- SNP6.0      no gains of 8, 1q or loss 16q

*inv*(X)(p11.22p11.4)

**Pierron et al 2012**

# Undifferentiated Sarcomas

- MFH label abandoned
- Pleomorphic RMS, LMS, LPS etc.
- Dedifferentiated liposarcoma
- UPS = diagnosis of exclusion base on morphology/IHC



THE END